Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma

The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...

Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma

Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...

Selinexor Combination Approved for Patients with Multiple Myeloma

The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received...

FDA Lifts Clinical Hold on Study Evaluating UCARTCS1 for Myeloma

The FDA has lifted its clinical hold on the phase I MELANI-01 trial evaluating the chimeric antigen receptor (CAR) T-cell therapy UCARTCS1 for the...

Simon Harrison: Early Data on AMG 701 for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Simon Harrison, MBBS, PhD, shares results from a phase I first-in-human trial evaluating AMG 701, an anti‑BCMA BiTE® molecule, in patients with heavily pre‑treated...
On location

Idecabtagene Vicleucel Leads to High Response Rates in Relapsed/Refractory Myeloma

Three-quarters of patients with heavily pretreated multiple myeloma (MM) responded to treatment with the BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel),...

Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

Alfred Garfall, MD, discusses updated safety and efficacy data from a phase I trial evaluating teclistamab, a bispecific BCMA x CD3 antibody, for the...